Search Medical Condition
Please enter condition
Please choose location from dropdown

East Hills, New York Clinical Trials

A listing of East Hills, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (821) clinical trials

A Prospective Multicenter Post Approval Study of the ReShape Integrated Dual Balloon System in Obese Subjects

The ReShape Post Approval Study is a post-approval, multicenter, single arm, open label clinical study intended to collect valid scientific evidence regarding the safety and efficacy of the ReShape Dual Balloon as an adjunct to diet and exercise in the treatment of BMI 30-40 subjects with one or more obesity-related ...

Phase N/A

0.94 miles

Learn More »

Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs

The investigators propose to recruit 1800 overweight/obese youth with Bipolar Spectrum Disorder (BSD) who are prescribed second generation anti psychotics (SGAs) from at least 24 public and private mental health practices in the Greater Cincinnati and New York City regions, (approximately 900 each from ~12 Cincinnati region and ~12 Long ...

Phase

0.94 miles

Learn More »

Obalon Post-Approval Study

The Obalon Balloon System - Post-Approval Study is a prospective, observational, and multi-center study.

Phase N/A

0.94 miles

Learn More »

RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease

To evaluate the effect of treatment with rifalazil versus placebo taken once weekly for 12 weeks on carotid atherosclerotic disease progression in patients who test positive for Chlamydia pneumoniae. Measurements of the carotid artery wall (intima-media thickness) and plaque characteristics will be evaluated with high-resolution magnetic resonance imaging (MRI) and ...

Phase

1.13 miles

Learn More »

Empagliflozin Impact on Hemodynamics in Patients With Diabetes and Heart Failure

A 12-week randomized, double-blind, placebo-controlled trial to explore the effects of once-daily empagliflozin 10mg on hemodynamic parameters (pulmonary artery pressures) in patients with type 2 diabetes mellitus and heart failure (reduced or preserved ejection fraction, ischemic or non-ischemic etiology) who already have a CardioMEMs device implanted for non-study related clinical ...

Phase

1.13 miles

Learn More »

RESOLUTE ONYX Post-Approval Study

To observe the continued performance of the Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population.

Phase N/A

1.13 miles

Learn More »

MILD Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

Using the Centers for Medicare and Medicaid (CMS) Medicare Research Identifiable Files (RIFs) containing all medical claims for 100% of Medicare beneficiaries enrolled in the Medicare fee-for-service program, claims-based patient history and demographics will be combined with longitudinal analyses. In this study, the control group will include all patients receiving ...

Phase N/A

1.13 miles

Learn More »

Physiologic Assessment of Coronary Stenosis Following PCI

This is a pilot study designed to assess the relationship between iFR pullback and the distribution of coronary atheroma/stenoses as assessed by Quantitative Coronary Angiography (QCA) post angiographically successful PCI.

Phase N/A

1.13 miles

Learn More »

Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

This trial will evaluate Orbital Atherectomy compared to conventional balloon angioplasty technique for the treatment of severely calcified lesions prior to implantation of drug-eluting stents (DES).

Phase N/A

1.13 miles

Learn More »

Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

The purpose of this study is to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF.

Phase

1.13 miles

Learn More »